Compare IPCA Labs with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs NATCO PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS NATCO PHARMA IPCA LABS/
NATCO PHARMA
 
P/E (TTM) x 23.3 42.0 55.5% View Chart
P/BV x 8.4 6.0 139.7% View Chart
Dividend Yield % 0.1 0.6 25.7%  

Financials

 IPCA LABS   NATCO PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-19
NATCO PHARMA
Mar-19
IPCA LABS/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,042849 122.7%   
Low Rs590557 105.9%   
Sales per share (Unadj.) Rs298.6573.8 52.0%  
Earnings per share (Unadj.) Rs35.0176.0 19.9%  
Cash flow per share (Unadj.) Rs49.4198.2 24.9%  
Dividends per share (Unadj.) Rs3.006.25 48.0%  
Dividend yield (eoy) %0.40.9 41.4%  
Book value per share (Unadj.) Rs247.1842.7 29.3%  
Shares outstanding (eoy) m126.3536.50 346.2%   
Bonus / Rights / Conversions ESOSBB-  
Price / Sales ratio x2.71.2 223.1%   
Avg P/E ratio x23.34.0 583.7%  
P/CF ratio (eoy) x16.53.5 465.4%  
Price / Book Value ratio x3.30.8 395.9%  
Dividend payout %8.63.6 241.4%   
Avg Mkt Cap Rs m103,10825,660 401.8%   
No. of employees `00013.45.0 271.2%   
Total wages/salary Rs m7,8743,559 221.2%   
Avg. sales/employee Rs Th2,807.04,225.3 66.4%   
Avg. wages/employee Rs Th585.8718.0 81.6%   
Avg. net profit/employee Rs Th329.01,295.9 25.4%   
INCOME DATA
Net Sales Rs m37,73220,945 180.1%  
Other income Rs m5771,302 44.3%   
Total revenues Rs m38,30922,247 172.2%   
Gross profit Rs m6,9017,948 86.8%  
Depreciation Rs m1,824810 225.2%   
Interest Rs m189193 97.8%   
Profit before tax Rs m5,4658,247 66.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,0421,823 57.2%   
Profit after tax Rs m4,4226,424 68.8%  
Gross profit margin %18.337.9 48.2%  
Effective tax rate %19.122.1 86.3%   
Net profit margin %11.730.7 38.2%  
BALANCE SHEET DATA
Current assets Rs m23,77823,472 101.3%   
Current liabilities Rs m10,9757,287 150.6%   
Net working cap to sales %33.977.3 43.9%  
Current ratio x2.23.2 67.3%  
Inventory Days Days10492 112.5%  
Debtors Days Days6688 74.7%  
Net fixed assets Rs m20,36818,648 109.2%   
Share capital Rs m253365 69.2%   
"Free" reserves Rs m30,97134,525 89.7%   
Net worth Rs m31,22430,760 101.5%   
Long term debt Rs m1,4090-   
Total assets Rs m45,50743,031 105.8%  
Interest coverage x30.043.7 68.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.5 170.3%   
Return on assets %10.115.4 65.9%  
Return on equity %14.220.9 67.8%  
Return on capital %17.327.4 63.1%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30811,536 150.0%   
Fx outflow Rs m6,2662,939 213.2%   
Net fx Rs m11,0428,597 128.4%   
CASH FLOW
From Operations Rs m4,9236,688 73.6%  
From Investments Rs m-1,563-6,122 25.5%  
From Financial Activity Rs m-1,832-509 359.9%  
Net Cashflow Rs m1,52866 2,314.7%  

Share Holding

Indian Promoters % 45.9 52.0 88.2%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 11.4 7.8 145.4%  
FIIs % 25.3 16.6 152.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 26.0 66.9%  
Shareholders   36,892 25,395 145.3%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ALEMBIC  AUROBINDO PHARMA  STERLING BIOTECH  FDC  SUN PHARMA  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 222 Points Higher; Asian Paints and Axis Bank Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors(Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

My 'Unlock' Investments(Fast Profits Daily)

Jun 11, 2021

The best unlock investments you can make in the market.

The Most Visible Sign of India's Revival is on Two Wheels(Profit Hunter)

Jun 9, 2021

Investing in the best stocks could result in wealth compounding on a massive scale.

Rs 2 Trillion Stimulus Coming to a Stock Market Near You(Profit Hunter)

Jun 2, 2021

Get ready to profit from a massive stimulus that you've never seen before.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 15, 2021 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS